The CD19–CD21 Complex Regulates Signal Transduction Thresholds Governing Humoral Immunity and Autoimmunity  by Tedder, Thomas F et al.
Immunity, Vol. 6, 107–118, February, 1997, Copyright 1997 by Cell Press
The CD19–CD21 Complex Regulates Signal Review
Transduction Thresholds Governing
Humoral Immunity and Autoimmunity
Thomas F. Tedder, Makoto Inaoki, and Shinichi Sato Structure and Function of the CD19 Complex
The structure and in vitro function of the CD19–CD21Department of Immunology
Duke University Medical Center complex has been reviewed recently (Tedder et al.,
1994). CD19 is a member of the immunoglobulin super-Durham, North Carolina 27710
family with a cytoplasmic region of z240 amino acids
(Tedder and Isaacs, 1989). The amino acid sequences of
the cytoplasmic region of human CD19 (hCD19), mouseIntroduction
CD19 (mCD19), and guinea pig CD19 are highly homolo-B lymphocytes respond to numerous stimuli that regu-
gous, consistent with a critical role for this region inlate negative selection in the bone marrow, the genera-
CD19 function (Bradbury et al., 1993; Zhou et al., 1991).tion of humoral immune responses in the periphery, and
The cytoplasmic region of CD19 contains localized re-the establishment and maintenance of tolerance and
gions of strong net negative charge (Table 1) with ninememory. The outcome of these developmental re-
conserved tyrosine residues, which may mediate its in-sponses is determined in part by signal transduction
teractions with the proto-oncogene Vav, phosphatidyl-through theB cell antigen (Ag)–receptor complex (Good-
inositol-3 kinase (PI-3 kinase), and the Lyn, Lck, andnow, 1996). These signals are further regulated or “fine-
Fyn protein tyrosine kinases (Chalupny et al., 1995;tuned” by an array of cytoplasmic signal transduction
Tuveson et al., 1993; Uckun et al., 1993; van Noesel et al.,molecules that amplify or dampen Ag–receptor signals
1993b; Weng et al., 1994). Sites of potential interactionsduring B cell development and during responses to self
between CD19 and Ablor 3BP2 have also been identifiedor foreign Ags. These downstream “response regula-
(Songyang et al., 1993, 1994).tors” may be kinases, phosphatases, or other molecular
CD19 physically associates with CD21 on the surfacemediators that greatly influence the magnitude and out-
of human B cells (Bradbury et al., 1992; Matsumoto etcome of transmembrane signaling events. Cell surface
al., 1991). CD21 contains an extracellular domain of 15 orresponse regulators may also inform B cells of their
16 repeating structural elements called short consensusextracellular microenvironment and thereby define sig-
repeats (SCRs), a membrane-spanning region, and a 34naling thresholds within the B cell. Once signaling
amino acid cytoplasmic domain (Moore etal., 1987; Weisthresholds are established, transmembrane signaling
et al., 1986). hCD21 and mCD21 are receptors for iC3b,events are interpreted in a predetermined context and
C3d,g, and C3d. In addition, hCD21 is a receptor for theappropriate responses are initiated. For example, imma-
Epstein–Barr virus (Fingeroth et al., 1984; Nemerow etture B cells undergo apoptosis or clonal tolerance fol-
al., 1985). hCD21 can also physically associate with alowing surface Ag–receptor cross-linking, while this
structurally similar complement receptor, CD35 (CR1),stimulus leads to a proliferative response in mature B
and generate a receptor complex that does not containcells (Cooper et al., 1980).Divergent response regulators
CD19 (Tuveson et al., 1991). hCD35 is expressed by Bmay influence these events by either positively or nega-
cells, erythrocytes, neutrophils, monocytes, and sometively biasing the context of Ag–receptor signals during
T cells (Tedder et al., 1983; Wilson et al., 1983). In con-distinct stages of development.
trast with their human counterparts, which are encodedPotential response regulators on the surface of B cells
by distinct genes, mCD35 is generated by the additioninclude CD19, which forms a complex with CD21 (com-
of six SCRs to the amino-terminal end of the mCD21plement receptor type 2 [CR2]), CD81, and Leu-13 (Ted-
protein by differential gene splicing. C3 cleavage prod-der et al., 1994). Ligation of members of the CD19 com-
ucts form covalent bonds with foreign Ags or immuneplex initiates a cascade of biological responses that
complexes generating C3b–Ag complexes. In both hu-can modulate signal transduction through the B cell
man and mouse, CD35 serves as a cofactor for theAg–receptor complex and other cell surface receptors
hydrolysis of the C3b–Ag complex into C3d, g–Ag, which(Figure 1A). Recent studies with mice that lack CD19 or
allows CD21 binding (reviewed by Ahearn and Fearon,CD21 or overexpress CD19 suggest that the CD19–
1989). This process is important for the processing ofCD21 complex serves as a general response regulator
Ag–antibody complexes and the final deposition ofthat governs humoral immune responses by B cells.
C3d–Ag complexes on the surface of B cells and follicu-Furthermore, CD21 is a receptor for the iC3b, C3d,g,
lar dendritic cells through CD21.and C3d cleavage fragments of the third complement
CD19 also associates directly with CD81, a membercomponent (C3), which play a major role in host defense
of the tetraspans family of proteins that includes CD9,against infection. By itself, complement is an element
CD37, CD53, CD63, and CD82 (Bradbury et al., 1992;of the innate immune system that can become activated
Levy et al., 1991). CD81 is expressed by most B lineageby the alternative pathway in response to foreign micro-
cells and by a wide variety of cell types including mostorganisms. In conjunction with the immunoglobulin M
lymphocytes, natural killer cells, thymocytes, eosino-(IgM) and IgG products of humoral immunity, comple-
phils, neuroblastomas, melanomas, and fibroblasts (En-ment can become activated via the classical pathway.
gel et al., 1994; Oren et al., 1990). Members of the tet-Thus, the binding of C3 fragments to the CD19–CD21
raspans family associate with a variety of cell surfacecomplex further integrates the innate complement sys-
molecules in different cell lineages and have been impli-tem with humoral immunity (Fearon and Carter, 1995;
Tedder et al., 1994). cated in the regulation of cell growth, motility, and
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Figure 1. Structure and Expression of Mem-
bers of the CD19 Complex
(A) CD19, CD21, CD81, and Leu-13 associate
on the surface of B cells to generate the CD19
complex. Potential signaling interactions
among the B cell Ag–receptor complex (IgM,
CD79a, CD79b), the CD19 complex, and the
CD45 protein tyrosine phosphatase are in-
dicated. Arrows indicate potential signal
transduction pathways. Abbreviations are as
follows: Y, sites of potential tyrosine phos-
phorylation in CD19; PPP, potential sites of
SH3 domain interactions; Ag, antigen; ITAM,
immunoreceptor tyrosine-based activation
motif; PLC, phospholipase C; PI, phosphati-
dylinositol; PIP2, phosphatidylinositol (4,5)bis-
phosphate; DAG, diacylglycerol; IP3, inositol
(1,4,5)trisphosphate; PIP3, phosphatidylinosi-
tol (3,4,5)trisphosphate; PI-3 kinase, phos-
phoinositide-3 kinase.
(B) Expression of CD19, CD21, and CD35 dur-
ing B cell development in humans and mice.
The horizontal bars represent the relative cell
surface density of Ag expression.
signaling. CD81 physically associates with another mol- the function of Leu-13/9-27 is unknown, it has been
implicated in the anti-proliferative activity of interferon,ecule, Leu-13, generating a bimolecular complex ex-
pressed by B cells and other cell types (Bradbury et al., as well as general growth regulation.
Regulated Expression of the CD19 Complex1992; Takahashi et al., 1990). Leu-13 is identical to the
9-27 gene product, a member of an interferon-inducible Expression of hCD19 is restricted to B lineage cells and
follicular dendritic cells, with a gradual increase in Bgene family containing three highly homologous pro-
teins (Deblandre et al.,1995; Lewin etal., 1991). Although cell expression with maturation (Figure 1B). In mice,
Table 1. Structural Features of the CD19 Cytoplasmic Domain
SH2-Bearing
Exon Amino Acids Basic (%) Acidic (%) Potential SH2 Motif Molecules
6 17 8 (47) 1 (6) None
7 29 1 (3) 0 Y330GNV ?
8 38 3 (8) 2 (5) Y360GNP ?
9 35 0 15 (43) Y391EEP Vav, Abl, Nck
Y403END Fyn, 3BP2
10 23 0 9 (39) Y421ENP Abl, 3BP2
11 19 1 (5) 6 (32) Y443ENE Fyn, 3BP2
12 19 2 (11) 3 (16) None
13 31 4 (13) 4 (13) Y482EDM p85
Y490AAP ?
14 30 2 (7) 6 (20) Y513ENM p85
Amino acid composition and positions of hCD19 are as described previously (Tedder and Isaacs, 1989; Zhou et al., 1991).
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the majority of early B lineage cells express mCD19 at dependent and independent responses of B cells and
may be a highly regulated central signaling element thatrelatively high levels (Figure 1B), even at the pro-B cell
stage (Krop et al., 1996; Sato et al., 1996b). There is is linked, perhaps via tyrosine phosphorylation, to multi-
ple cell surface receptors and signaling pathways.a specific 2.5-fold increase in mCD19 expression that
correlates with the transition from an immature B220lo When the CD19 complex and surface immunoglobulin
are cross-linked, signals induced through each receptorB cell to a mature B220hi B cell in the bone marrow (Sato
et al., 1996b). B-1 lineage B cells (CD51, IgMhi, IgDlo, and may synergize and provide a stronger stimulus for induc-
ing B cell proliferation (Figure 1A). Ligation of surfaceB220lo) within the peritoneum express mCD19 at levels
.50% higher than on conventional B cells (Krop et al., immunoglobulin results in activation of the CD79-asso-
ciated tyrosine kinases Blk, Fyn, Lyn, and Syk. Ligation1996; Sato et al., 1996b). B-1 cells are the predominant
B cell subpopulation found in the peritoneal cavity of of the Ag–receptor complex induces tyrosine phosphor-
ylation of the CD19 cytoplasmic domain, thereby gener-adult mice and are thought to represent either a distinct
subset or lineage of B cells (Hardy et al., 1994; Haughton ating effective Src homology 2 domain (SH2)-binding
sites for key regulatory enzymes that promotes theiret al., 1993; Kantor, 1991). CD21 appears on the surface
of human and mouse B cells at about the same time recruitment to the cell surface. Fyn, Lyn, Lck, Vav, and
PI-3 kinase are found in immunoprecipitated CD19 com-as IgD (Figure 1B) and is also expressed by follicular
dendritic cells (Molina et al., 1990; Tedder et al., 1984). plexes, and cross-linking of CD19 leads to kinase activa-
tion and phosphoinositide generation in some casesCD35 appears early in human B cell development (Ted-
der et al., 1983), but is not a component of the hCD19 (Chalupny et al., 1993, 1995; Tuveson et al., 1993; Uckun
et al., 1993; van Noesel et al., 1993a). Tyrosine-phos-complex. Since the outcome of CD19 complex signaling
may vary depending on the overall composition of the phorylated CD19 is also reported to bind with low affinity
to phospholipase C-g1 (PLC-g1), GAP, and Yes (Cha-complex during B cell differentiation, the transition from
being a CD19loCD212 immature B cell to a CD19hiCD211 lupny et al., 1993), although these associations may be
indirect. Binding of the p85 subunit of PI-3 kinase tomature B cell is likely to be a developmental milestone
that contributes to the responsiveness of B cells to CD19 localizes PI-3 kinase to the membrane, which may
be important for access of PI-3 kinase to substrates.transmembrane signals. Since CD81 and Leu-13 are
broadly expressed by multiple leukocyte lineages, the Activated Lyn and Fyn may also bind to the p85 subunit
of PI-3 kinase and amplify kinase activation (YamanashiCD81–Leu-13 complex may represent a general signal
transduction complex with functional importance to a et al., 1993). Fyn binds phosphorylated CD19 at sites
proximal to the PI-3-binding sites, which suggests thatvariety of cell types. However, its associations with lin-
eage-specific signaling elements such as the CD19 CD19 binds Fyn and PI-3 kinase concurrently. The sub-
sequent binding of Fyn SH3 domains to PI-3 kinase maycomplex in B cells may result in the genesis of signaling
activities that are novel to each complex. activate PI-3 kinase (Chalupny et al., 1995). A similar
role for Vav SH3 domains in activation of PI-3 kinaseFunction of the CD19 Complex In Vitro
In vitro studies examining the effects of ligating CD19 following CD19 binding (Figure 1A) has also been pro-
posed (Weng et al., 1994). Signaling through CD19 in-complex members with monoclonal antibodies (MAbs)
have consistently indicated a role for CD19 in the acti- duces formation of a CD19–Vav–PI-3 kinase complex,
which activates the Vav–mitogen-activated protein ki-vation and growth regulation of B cells (reviewed by
Tedder et al., 1994). Engagement of CD19 by MAbs nase pathway. In addition, engagement of CD19 results
in activation of PLC and the subsequent generation ofleads to tyrosine phosphorylation of cytoplasmic and
cell surface proteins including CD19, activation of phos- diacylglycerol, which activates protein kinase C, and the
generation of inositol 1,4,5-trisphosphate (IP3), whichpholipase C (PLC), inositol phospholipid turnover, intra-
cellular Ca21 ([Ca21]i) mobilization, stimulation of serine- induces release of intracellular calcium. Collectively,
these results suggest that CD19 serves as a centralspecific protein kinases including protein kinase C, and
activation of nuclear factor kB. In most cases, these regulatory component upon which multiple signaling
pathways converge.signals complement or modulate the regulatory signals
of other receptors, particularly the Ag–receptor complex
(Figure 1A). The signaling capability of CD19 is not de- Models of CD19–CD21 Function In Vivo
CD19-Deficient Micependent on the expression of surface immunoglobulin,
since CD19 ligation can provide proliferative signals for The development of two independent lines of CD19-
deficient mice has provided new insight into CD19 func-surface IgM2 precursor B cells (Chalupny et al., 1993;
Uckun et al., 1993). Furthermore, the CD19 complex tion (Engel et al., 1995; Rickert et al., 1995). A dominant
feature of these mice is their dramatic loss (75%–90%)does not require CD21 for signal transduction (Bradbury
et al., 1993). In mature B cells, CD19 or CD21 cross- of peritoneal B-1 lineage cells, which normally express
the highest levels of CD19. One line of CD19-deficientlinkingwith either the Bcell Ag–receptor complex, CD40,
or CD72 generates synergistic transmembrane signals mice has a small decrease in the number of immature
B cells and a small increase in mature B cells in thegreater than those generated through each receptor
alone (Carter and Fearon, 1992; Kozono et al., 1995; bone marrow, but a significant decrease (55%) in con-
ventional B cells within the periphery (Engel et al., 1995;Rigley and Callard, 1991; Uckun et al., 1993). Further-
more, CD19 becomes rapidly phosphorylated on tyro- Sato et al., 1997). B cells from this line of mice also
have a significantly decreased capacity to proliferate insine residues following engagement of the B cell Ag–
receptor complex, CD40, or CD72 (Uckun et al., 1993). response to B cell mitogens, including lipopolysaccha-
ride (LPS), anti-IgM antibodies, and CD40 ligation (EngelTherefore, engagement of CD19 plays a role in Ag-
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et al., 1995). Although CD19-deficient mice generate is likely to have considerable functional significance.
The .50% increase in CD19 expression by B-1 cellsnormal acute [Ca21]i responses following surface IgM
may also be functionally significant (Sato et al., 1996b)cross-linking, elevated levels of [Ca21]i persist for a
and may explain in part why B-1 lineagecells are particu-longer duration when compared with wild-type B cells
larly sensitive to anti-CD19 MAb treatment in vivo (Krop(Sato et al., 1997). Therefore, CD19 function is not re-
et al., 1996).quired for B cell function, but appears to play a general
B cells from mice that overexpress CD19 demonstraterole in the amplification of B cell responses to a variety
heightened in vitro proliferative responses (Engel et al.,of signals during development and activation.
1995; Sato et al., 1997; Zhou et al., 1994). Notably, theseCD19-deficient mice have an overall z75% reduction
B cells have higher spontaneous proliferative responsesin serum immunoglobulin levels, with substantial de-
when cultured in the absence of mitogens and remaincreases in IgM, IgG1, and IgG2a (Engel et al., 1995;
viable longer. These B cells also generate 2- to 3-foldRickert et al., 1995). In these mice, humoral immune
higher levels of proliferation in response to IgM cross-responses to T cell–dependent Ags are modest and do
linking, LPS, and CD40 ligation. Serum immunoglobulinnot undergo affinity maturation (Engel et al., 1995; Rick-
levels in mice that overexpress CD19 are also signifi-ert et al., 1995; Sato et al., 1995). Following immunization
cantly higher than in wild-type littermates, despite thewith different T cell–independent Ags, CD19-deficient
dramatic decrease in the number of peripheral B cells.mice generate reduced, normal, or significantly aug-
Furthermore, B cells that overexpress CD19 exhibit re-mented humoral responses (Rickert et al., 1995; Sato et
ciprocal humoral immune responses when comparedal., 1995). Decreased humoral responses correlate with
with CD19-deficient mice. Mice that overexpress CD19a general lack of secondary follicle and germinal center
generate significantly augmented responses to most Tformation within lymphoid tissues of CD19-deficient
cell–independent and dependent Ags, yet generate re-mice both before and following Ag challenge (Rickert et
duced responses following immunization with a T cell–al., 1995; Sato et al., 1995). Although germinal centers
independent type 2 Ag (Sato et al., 1995). Germinal cen-can form in CD19-deficient mice, they occur at a signifi-
ters in mice that overexpress CD19 are smaller thancantly reduced rate and level of magnitude (Sato et al.,
those of wild-type mice, although their numbers are1995). Since the ability of CD19-deficient B cells to un-
similar. Following immunization, germinal centers indergo differentiation, antibody secretion, and isotype
mice that overexpress CD19 remain small and do not
switching in vitro are not overtly impaired (Sato et al.,
increase in number. Therefore, small changes in the
1995), the hypogammaglobulinemia of CD19-deficient
overall levels of CD19 expressed by B cells as they
mice may result from defects manifest during the early
mature may have a considerable impact on their func-
stages of B cell activation, resulting in poor primary
tional responses to transmembrane signals. While CD19-
responses and retarded germinal center formation.
deficient mice are hyporesponsive to most trans-
Mice That Overexpress CD19 membrane signals, mice that overexpress CD19 are
Mice that express a hCD19 transgene,and thereby over- hyperresponsive.
express CD19, provide additional insight into CD19 Consistent with CD19 regulating signaling thresholds,
function in vivo (Zhou et al., 1994). Expression of the B cells from the blood and spleen of mice that lack or
hCD19 gene under the control of its endogenous pro- overexpress CD19 have unusual cell surface pheno-
moter is restricted to B lineage cells and appears early types (Sato et al., 1996b, 1997). Most peripheral B cells
in development, consistent with the expression of CD19 from CD19-deficient mice express cell surface IgM at
in humans (Figure 1B). hCD19 can replace mCD19 func- significantly greater levels than wild-type mice. By con-
tion when expressed at physiologically appropriate cell trast, most peripheral B cells from mice that overexpress
surface site densities (Sato et al., 1996b, 1997). Thus, CD19 have a distinct IgMloIgDhiCD21/35lo-med phenotype
the immunodeficiencies manifest in CD19-deficient and have increased major histocompatibility complex
mice can be restored by reintroducing hCD19 expres- class II Ag expression, but are not overtly activated.
sion. Overexpression of even low levels of hCD19 has This phenotype is unlikely to result from significant
readily detectable effects on B cell development, while changes in B cell maturation or selection in the bone
mice that overexpress CD19 at 2- or 3-fold physiologic marrow (Engel et al., 1995; Rickert et al., 1995). Rather,
levels have dramatic alterations in B cell development this phenotype is similar to that of anergic B cells that
(Engel et al., 1995; Sato et al., 1997; Zhou et al., 1994). have been chronically exposed to soluble autoantigens
Overexpression of CD19 severely impairs the generation in vivo (Cooke et al., 1994; Cyster and Goodnow, 1995;
of mature B cells in the bone marrow, resulting in dra- Goodnow et al., 1988). Although the remaining IgM and
matically reduced numbers of conventional B cells IgD receptors expressed by anergic B cells are desensi-
within the blood and peripheral lymphoid tissues. For tized and are unable to activate tyrosine kinases effec-
example, mice that express 3-fold higher levels of CD19 tively or trigger intracellular calcium increases (Cooke
have a .80% decrease in the number of conventional et al., 1994), B cells that overexpress CD19 are hyperre-
B cells within the periphery (Engel et al., 1995; Sato et sponsive to IgM cross-linking and generate normal
al., 1997; Zhou et al., 1994). By contrast, the number of [Ca21]i responses (Zhou et al., 1994). Therefore, the most
B-1 lineage cells within the peritoneum and spleen is likely explanation for this phenotype is that overexpres-
dramatically increased in mice that overexpress CD19 sion of CD19 alters signal transduction thresholds and
(Sato et al., 1996b, 1997). Since the regulation of CD19 thereby renders B cells more susceptible to transmem-
cell surface sitedensity is a critical factor for maintaining brane signals. This situation mimics the chronic signal-
normal B cell development, the 2.5-fold increase in ing that occurs in B cells exposed to autoantigens in
vivo.mCD19 expression levels on mature B cells (Figure 1B)
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Figure 2. CD19 May Govern B Cell Selection
and Clonal Expansion
Potential effects of CD19 deficiency and
overexpression of hCD19 on (A) immature B
cells within the bone marrow and (B) mature
B cells within the periphery. B cells bind for-
eign or self-Ags through high or low affinity
Ag–receptors (immunoglobulin) as indicated.
Ligation of the CD19 complex and the Ag–
receptor initiate a series of signaling events
with varying intensities dependent on the ex-
tent of CD19 ligation and the nature of Ag
binding (arrows). The cumulative effects of
CD19 signal transduction and Ag–receptor
signaling lead to a variety of biological conse-
quences, including clonal deletion, escape to
the periphery, and proliferation (prolif.).
Models of CD19 Function immunological tolerance to self-Ags is achieved in part
by the clonal deletion of immature B cells that expressThe characteristics of CD19-deficient mice and mice
that overexpress CD19 suggests that CD19 serves as a high affinity IgM receptors that are reactive with self-
Ags (Goodnow, 1992; Hartley et al., 1993; Nemazee andgeneral rheostat for the regulation of B cell responses
to mitogens and other signals essential for development Bu¨erki, 1989). Selection also depends on the existence
of triggering thresholds for intracellular signals that areand differentiation. Since small (2- to 3-fold) changes in
CD19 expression levels have such dramatic effects on influenced by Ag valency and concentration, together
with receptor affinity (Goodnow, 1992; Nemazee et al.,B cells (Sato et al., 1997; Zhou et al., 1994), it is possible
that CD19 overexpression may imitate increased cell 1991). In this context, increased CD19 expression may
translate into the overproduction of intracellular signalssurface ligation of the CD19 complex and thus increase
the frequency of intracellular signaling events that es- that exceed the signaling threshold, which may result in
down-regulation of immature B cell development. Sincetablish intracellular signal transduction thresholds for
other receptors. As occurs with surface immunoglobu- many preimmune B cells produce self-reactive antibod-
ies (Kearney et al., 1992; Striebich et al., 1990), loweringlin, the outcome of altered CD19 function is manifest in
different ways depending on the differentiation state of the surface immunoglobulin signaling threshold for neg-
ative selection by overexpressing CD19 may explain thethe B cell. Models illustrating the potential role for CD19
during the development of immature B cells and mature severe deficiency of bone marrow B cells in these mice.
Thus, CD19 regulation of transmembrane signals gener-B cells are shown in Figure 2. Engagement by CD19 of
a putative ligand on an Ag-presenting cell is shown for ated through low affinity Ag–receptors may thereby lead
to increased clonal deletion of immature B cells in theillustrative purposes, since the existence of a CD19 li-
gand remains speculative. bone marrow. However, this hypothesis remains to be
formally proven, particularly in the case of CD19-defi-CD19 may regulate Ag-dependent negative selection
of immature B cells during maturation in the bone mar- cient B cells bearing high affinity Ag–receptors (Fig-
ure 2A).row (Figure 2A). Before B cells leave the bone marrow,
Immunity
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Activation and proliferation of peripheral B cells is Complement-Deficient Animals
Complement deficiencies that affect C3 activation inalso likely tobe influenced by CD19 function. Stimulation
humans, guinea pigs, and dogs result in diminished hu-of B cells through high or low affinity antigen receptors
moral responses to foreign Ags that mimic events thatresults in either normal or weak proliferation, respec-
follow the in vivo depletion of C3 by cobra venom factortively (Figure 2B). In the case of B-1 lineage cells, weak
(Bo¨ttger et al., 1985; Finco et al., 1992; Jackson et al.,mitogenic signals generated through their low affinity
1979; O’Neil et al., 1988; Ochs et al., 1983). InheritedAg–receptors may induce only modest clonal expan-
C3 deficiencies have profound effects on primary andsion. In the case of CD19-deficient B cells, even strong
secondary antibody responses to T cell–dependent Agsmitogenic signals generate only modest proliferative re-
and some T cell–independent Ags (Bitter-Suermann andsponses. In cases where CD19 is overexpressed, B cells
Burger, 1989). Studies of C3- and C4-deficient mice gen-bearing either low affinity or high affinity Ag–receptors
erated by gene targeting further verify the role of com-exhibit greater than normal proliferative responses. En-
plement in humoral immunity (Fischer et al., 1996; Wes-hanced clonal expansion may explain why peripheral B
sels et al., 1995). C3- or C4-deficient mice have nocell numbers are not as severely diminished in mice that
obvious abnormalities in either B cell or T cell develop-overexpress CD19 while large numbers of precursors
ment, phenotype, or numbers. However, serum IgG1,are removed in the bone marrow. The same may also
IgG2a, and IgG3 levels are 33%–53% of wild-type levelsbe true for B-1 cells that overexpress CD19, where their
in C4-deficient mice, while C3-deficient mice have nor-clonal expansion may be driven by weak self-Ags and
mal levels of all immunoglobulin isotypes. B cells fromaugmented CD19 function. This model of CD19 function
both C3- and C4-deficient mice proliferate normally inalso correlates with the hyporesponsive phenotype of
response to LPS, anti-IgM antibodies, or CD40 ligation.CD19-deficient mice and the hyperresponsive nature of
However, C3- and C4-deficient mice exhibit severe de-mice that overexpress CD19. Since B cell Ag–receptors
fects in both their primary and secondary antibody re-are generally of low avidity prior to clonal selection and
sponses to T cell–dependent Ags, even at high Agaffinity maturation, this hypothesis has important impli-
doses. These defects are characterized by a failure incations for B cell development, as well as activation in
isotype switching and a reduction in the number of ger-response to antigenic stimulation in the periphery.
minal centers generated within splenic follicles. Re-
sponses to T cell–independent Ags have yet to be re-
ported.Complement Activation as a Regulator
CD21/35-Deficient Miceof Humoral Immunity
Recent in vivo studies suggest a direct role for CD21 inAlthough CD19 function may be elicited following its
immune responses. Pretreatment of mice with a mCD21/potential binding to an as yet unidentified ligand, C3d
35 MAb blocks both T cell–dependent and independentbinding to CD21 supplies an already characterized li-
immune responses and the generation of immunologicalgand for the CD19 complex, thereby linking complement
memory (Gustavsson et al., 1995; Heyman et al., 1990;activation and B cell function. This hypothesis was first
Wiersma et al., 1991). The infusion of soluble recombi-suggested 25 years ago in experiments showing that the
nant mCD21 also blocks immune responses to T cell–transient depletion of C3 in mice impairs the subsequent
dependent Ags invivo (Hebell et al.,1991). Similar resultsinduction of humoral responses (Pepys, 1972). It was
have been obtained with two lines of CD21/35-deficientthen proposed that initiation of the complement cascade
mice (Ahearn et al., 1996; Molina et al., 1996). One lineprovided a second signal for B cell activation via C3
of CD21/35-deficient mice that produces only low levels(Dukor and Hartmann, 1973; Pepys, 1976). Considerable
of CD21/35 protein has an z40% reduction in the fre-experimental evidence has now verified that C3 deple-
quency of CD51 peritoneal B-1 cells (Ahearn et al., 1996),
tion with cobra venom factor, an analog of mammalian
while a line completely lacking CD21/35 has normal
C3 convertase in snakes, leads to impaired humoral
numbers of B-1 cells (Molina et al., 1996). Nonetheless,
responses to T cell–dependent and some T cell–
both lines of CD21/35-deficient mice have normal num-
independent Ags in mice (Pepys, 1974). In vivo comple- bers of splenocytes and well-developed splenic follicles.
ment depletion suppresses the production of IgG and The proliferative responses of B cells from CD21/35-
other T cell–dependent antibody classes much more deficient mice are normal in response to LPS, anti-IgM
significantly than T cell–independent IgM responses. antibodies, or CD40 ligation. Serum immunoglobulin lev-
Transient depletion of C3 also completely abrogates the els are generally within the normal range, while IgG2a,
development of memory B cells (Klaus and Humphrey, IgG2b, and IgG3 levels are reduced by 20%–66%. How-
1977). However, once normal priming has occurred, ever, CD21/35-deficient mice exhibit severe defects in
depletion of complement during a secondary immuniza- their primary and secondary humoral responses to T
tion has a less dramatic suppressive effect on antibody cell–dependent Ags. IgM titers are moderately de-
responses. The requirement for complement is not ab- creased, while there is a dramatic impairment in the IgG
solute, since the administration of large doses of Ag or response, particularly the IgG1 and IgG3 responses. A
the use of adjuvants can compensate for induced or significant reduction in the number and size of germinal
congenital complement deficiencies (Bitter-Suermann centers induced within splenic follicles following sec-
and Burger, 1989; Ochs et al., 1983). This finding sug- ondary challenge was observed in one line of mice, while
gests that C3 depletion primarily affects an early phase this was not observed for the other line. Although CD19
expression alone did not compensate for a loss ofof B cell activation.
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Figure 3. Models of CD19 Complex Function
In Vivo
(A) Coligation of CD19 and the Ag–receptor
complex (IgM) by C3d covalently bound to
Ag amplifies B cell responses.
(B) Coligation of CD19 complexes by C3d co-
valently boundto Ag functions as a “response
regulator” that establishes signaling thresh-
olds that govern signaling events through
other cell surface receptors. Arrows indicate
potential signal transduction pathways. Ab-
breviations are as follows: LPS-R, LPS recep-
tor; IL-4 R, receptor for interleukin-4; Fcg R,
receptors for the Fc portion of IgG anti-
bodies.
mCD21/35, the loss of mCD21/35 expression results in also supported by studies reported over a decade ago
(Melchers et al., 1985, 1986). In these studies, cross-a phenotype that is similar to, but much more subtle
than, the phenotype of CD19-deficient mice. linked, but not soluble, human C3b and C3d stimulated
the proliferation of activated, but not resting, mouse BMechanism of C3 Effects on Humoral Immunity
The exact mechanism by which complement deficiency cells. It was proposed that monocyte-derived C3 frag-
ments regulate an early phase of cell cycle progressionor depletion affects the humoral immune response re-
mains uncertain. In all models, the covalent coupling of initiated following Ag–receptor cross-linking, perhaps
through interactions with CD21. More recently, a novelC3 cleavage products onto Ags or immune complexes
facilitates their clearance via the reticuloendothelial sys- C3 mRNA transcript has been identified that encodes a
truncated C3 protein (Cahen-Kramer et al., 1994). Celltem and the localization of Ag onto B cells and follicular
dendritic cells within germinal centers (Klaus and Hum- lines transfected with this cDNA secrete a costimulatory
factor that augments the proliferation of B cells in assaysphrey, 1977; Papamichail et al., 1975). Thereby, defec-
tive humoral immune responses in cases of complement with macrophage-depleted mouse splenic B cells. Since
the predicted protein product of this mRNA containsdeficiency may result from defective Ag localization or
presentation within the follicular areas of the spleen (or the CD21-binding site of C3, it may bind CD21 and send
costimulatory signals. While further experiments are re-both). However, the defect in humoral immune re-
sponses in CD21/35-deficient mice appears to reside quired to further verify these findings, these studies sug-
gest that C3 complexes may augment B cell functionwithin the B cell compartment. Chimeric mice with nor-
mal levels of CD21/35 on their follicular dendritic cells, directly.
Models of CD19 Complex Functionbut not on their B cells, have defects in humoral re-
sponses to Ags similar to those of CD21/35-deficient In one model explaining the roles of the CD19 complex
and C3 in B cell function (Figure 3A), the associationmice (Croix et al., 1996). Defective B cell function is
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by decreasing the signaling thresholds necessary for B
cell activation. In the absence of infection or other
immune stimulators, signaling thresholds would be
modified to suppress humoral responses against weak
self-Ags. This would explain why alterations in CD19
expression levels so profoundly affect all B cells, most
of which should not be exposed to their appropriate Ags
in vivo. Furthermore, this model may explain why the
loss or overexpression of CD19 alters signal transduc-
tion through Ag–receptor-independent pathways (Engel
et al., 1995; Sato et al., 1995). The functional conse-
quences of CD19 overexpression may therefore mimic
increased C3d levels resulting from ongoing immune
responses to infections, while complement deficiencies
may mimic some aspects of CD19 deficiency. However,
CD19 may also have signaling roles in addition to servingFigure 4. Multiple Response Regulators Govern Signaling Thresh-
olds in B Cells as a transducing element for CD21 engagement, since
In this model, response regulators with positive or negative effects the phenotype of CD21/35-deficient and C3-deficient
influence signaling through the B cell Ag–receptor complex (sIg). mice is more moderate than the CD19 deficiency.
The resulting signaling thresholds regulate negative selection in the While direct data proving either model are not avail-
bone marrow, the magnitude of antibody responses in the periphery, able, components of both models could regulate B cell
autoimmunity, and peripheral tolerance. In this context, high Ag
activation during different stages of differentiation. Whatlevels in the presence of low C3dlevels can initiate positivesignaling
remains unresolved is why C3 and the CD19 complexand generate humoral immune responses, as can low Ag levels in
appear to be more critical for T cell–dependent immunethe presence of high C3d levels.
responses than T cell–independent responses. In part,
this may be due to the different mechanisms by whichbetween CD19 and CD21 is envisioned to provide a
T cell–dependent and T cell–independent Ags activatemechanism for bridging the B cell Ag–receptor complex
B cells rather than intrinsic differences in B cell function.with the CD19 complex through C3d–Ag (van Noesel et
Alternatively, most T cell–dependent Ags used experi-al., 1993b). In support of this model, the simultaneous
mentally represent novel Ags that are distinct from thoseligation of CD19–CD21 and membrane immunoglobulin
previously encountered by the host. Therefore, alter-in vitro lowers the threshold required for signaling
ations in B cell signaling thresholds are manifest asthrough the Ag–receptor, thereby promoting more effec-
significantly impaired responses to these novel anti-tive immune responses. This model of CD19–CD21 func-
gens. By contrast, most of the T cell–independent Agstion is also supported by recent studies (Dempsey et
used experimentally mimic compounds normally en-
al., 1996). Sequentially linking three repetitive subunits
countered by the host throughout life. In these cases,
of recombinant C3dto a model Ag potentiated the induc-
the effects of B cell dysfunction may be less apparent,
tion of a [Ca21]i response by transgenic mouse B cells since humoral responses might have been previously
expressing high affinity Ag–receptors for the model Ag. elicited to these Ags or their homologs. Secondary hu-
Moreover, this recombinant model Ag was dramatically moral responses are elicited in cases of CD19, CD21,
more immunogenic than the unmodified Ag. However, or complement deficiencies, albeit at lower levels in
it is highly likely that the model Ag and Ag–(C3)3 compo- some instances. Thus, although T cell–independent Ag
nents used in these studies were multimeric since the responses do not appear to be as dramatically impaired
model antigen alone would not have cross-linked anti- as T cell–dependent responses, both responses may
gen receptors and induced an [Ca21]i response. There- be affected by intrinsic alterations in B cell signaling
fore, although the complex of Ag–(C3)3 appeared to li- thresholds.
gate surface Ag–receptors and CD21 more efficiently,
these experiments do not necessarily demonstrate that Innate Immunity and Autoimmunity
Ag receptors and CD21 are ligated together as envi- Low affinity IgM antibodies reactive with single-
sioned in Figure 3A. The enhanced immunogenicity of stranded DNA and other autoantigens may represent
the model Ag–(C3)3 complex could have resulted from naturally occurring components of the innate immune
other mechanisms, such as the more rapid transmission system. Since these autoantibodies cross-react with
of the Ag into the follicles of lymphoid tissues. components of microorganisms, they may serve as a
A different model of CD19 complex function is primary defense mechanism against infections. These
prompted by results obtained with CD19-, CD21-, and “natural” autoantibodies may be produced by B-1 cells
C3-deficient mice. This model predicts that endogenous (Murakami and Honjo, 1995) that represent either a dis-
humoral C3d levels may establish signaling thresholds tinct fetal B cell differentiation pathway that is main-
for B cells in an Ag-independent manner through cross- tained by the presence of natural autoantigens without
linking the CD19 complex (Figure 3B). In this model, the a requirement for T cell help, or B cells that have been
CD19 complex would serve as a sensing mechanism selected by certain T cell–independent Ags (Haughton
for detecting activation of the innate immune system et al., 1993; Kantor, 1991). Since the Ag–receptors ex-
and adjust signaling thresholds accordingly (Figure 4). pressed by B-1 cells are generally of low affinity, trans-
Complement activation during ongoing immune re- membrane signals generated by these Ags may be inca-
pable of maintaining the B-1 population during adultsponses would heighten the humoral immune response
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life in the absence of signals generated through CD19 C4 (Atkinson, 1992; Cook and Agnello, 1992; Petri et al.,
1993). These cases may result from disrupting the role(Figure 2B). Lowering signal transduction thresholds
through increased CD19 function may augment prolifer- of complement in the metabolism of immune complexes,
resulting in the prolonged existence of immune com-ative responses to weak or self-Ags and thereby explain
the clonal expansion of B-1 cells in mice that overex- plexes that inappropriately deposit within vessel walls
and cause systemic vasculitis or other symptoms (Atkin-press CD19. Thus, signaling thresholds important for
regulating the generation of B-1 cells may likewise regu- son, 1992; Lachmann and Walport, 1987). The inappro-
priate or prolonged generation of C3 fragments duringlate the generation of “natural” low affinity IgM anti-
bodies. immune complex disease or chronic infections may also
alter B cell signaling thresholds resulting in heightenedAntibodies reactive with single-stranded DNA and
other autoantigens are significantly reduced in CD19- immune responses to self-Ags. Complement cleavage
fragments binding to the CD19–CD21 complex may alsodeficient mice and significantly elevated in mice that
overexpress CD19 (Sato et al., 1996b). Although the skew the B cell repertoire toward autoreactivity by posi-
tive selection or the maintenance of autoreactive B cellmechanism by which CD19 regulates the naturalautoan-
tibody component of the innate immune system is un- clones. Since a variety of autoantibodies, such as anti-
DNA antibodies, are normally present in serum owingknown, the anti-DNA autoantibodies in mice that overex-
press CD19 are predominantly of the IgG isotype, which to the incomplete deletion or peripheral inactivation of
self-reactive B cells (Guilbert et al., 1982; Klinman et al.,are more typical of those generated by conventional B
cells. In fact, high affinity pathogenic IgG antibodies 1988), altered signaling thresholds may also invalidate
anergy and lead to a breakdown of tolerance. Alteredare generally produced by CD52 B cells (Murakami and
Honjo, 1995), particularly in MRL–lpr/lpr mice (Reap et signaling thresholds may also perpetuate the production
of autoantibodies, as occurs in some mouse modelsal., 1993). A potential consequence of CD19 complex
function could therefore be a switch from the generation of autoimmune disease. Although further work will be
required to determine the precise role of the CD19 com-of nonpathogenic IgM autoantibodies to pathogenic IgG
antibodies in conventional B cells, as well as the clonal plex in autoantibody formation, it is likely that signaling
thresholds contribute significantly to the developmentamplification of B cells generating autoantibodies with
pathogenic specificity. This may be clinically relevant, of both innate immunity and autoimmunity.
as the class switch of autoreactive IgM antibodies to IgG
is associated with the development of systemic lupus Future Directions and Conclusions
Understanding the signaling pathways that intersecterythematosus (SLE), a prototypic autoimmune disease
characterized by antibodies to DNA in association with with CD19 will provide considerable information about
how signaling thresholds are regulated. Clues are pro-systemic inflammation (Shirai et al., 1991). Since a role
for CD51 B-1 cells in pathogenic autoantibody re- vided by mice lackingsignal transduction molecules that
lead to abnormal B cell development and phenotype, assponses has been difficult to establish, increased num-
bers of B-1 cells in autoimmunity may signify altered B occurs in CD19-deficient mice (Table 2). Btk-deficient
mice and Xid mice with mutations in Btk both havecell signaling thresholds that lead to disease, rather than
a necessary role for B-1 cells as the source of autoanti- diminished numbers of B-1 and conventional B cells
(Hayakawa et al., 1986; Khan et al., 1995). Vav-deficientbodies. Thus, increased CD19 function may lead to
heightened B cell responsiveness to weak self-Ags and mice have similar defects (Tarakhovsky et al., 1995;
Zhang et al., 1995). The phenotype of mice that overex-up-regulation of innate immunity, resulting in the subse-
quent development of autoimmune disease. press CD19 is mimicked by B cells deficient in the SHP1
protein tyrosine phosphatase (Kozlowski et al., 1993;The development of autoimmune diseases is likely
also to involve a number of genetic factors as well as Schultz et al., 1993), Lyn (Wang et al., 1996), or cell
surface CD22 (O’Keefe et al., 1996; Sato et al., 1996a;defective host responses and infectious agents. In some
patients with SLE, disease is closely associated with Tedder et al., 1997). The similar involvement of CD19 and
these other regulatory molecules in the development ofgenetic deficiencies in the early components of the clas-
sical complement pathway, C1, C1 inhibitor, C2, C3, or conventional and B-1 B cells is unique and suggests that
Table 2. Phenotypic Characteristics of Mice with Genetically Altered Response Regulators of B Lymphocyte Signal Transduction
Genotype Conventional B Cells CD51/B-1 Cells
Negative Effects
CD19 deficient ↓ 50% decrease ↓↓ 80% decrease
CD21 deficient Normal ↓ 40% decrease
BTK deficient ↓ 40% decrease ↓↓↓ 99% decrease
Xid ↓↓ 70% decrease ↓↓↓ 99% decrease
Vav deficient ↓↓ zNormal Undetectable
Positive Effects
CD19 Overexpressed ↓↓ 70% decrease ↑↑↑ 210% increase
SHP1 defective ↓↓↓ ↑↑↑
CD22 deficient ↓ 50% decrease in circulating B cells ↑ Increase
Lyn deficient ↓ 50% decrease Normal
Arrows represent the relative effect of the genetic alteration on B cell development.
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